Abstract
Purpose
Bivalirudin (Angiox, The Medicine’s Company, Parsippany, NJ), a synthetic direct thrombin inhibitor, when compared with standard antithrombotic therapy (including unfractionated heparin [UFH] alone or plus a glycoprotein IIb/IIIa inhibitor) determines a significant decrease of major and minor bleeding and similar protection against ischemic events both in elective and in urgent percutaneous coronary intervention (PCI). There is a lack of prospective clinical trial assessing the safety and the efficacy of bivalirudin compared with UFH alone in the subset of biomarker negative patients at high risk of bleeding undergoing to elective PCI through the femoral approach.
Methods
This is a single-center, investigator-driven, randomized, double-blind, controlled trial (www.clinicaltrial.gov registration: NCT01465503). Consecutive patients at high bleeding risk (score ≥10 according to Nikolsky et al.) undergoing elective PCI through the femoral approach will be screened for eligibility. Included patients will be randomized (ratio 1.1) to bivalirudin (Bivalirudin group) and UFH (UFH group). The primary endpoint will be the rate of major bleeding (REPLACE 2 criteria). We expect a major bleeding rate ≥5 % in the UFH group versus a ≤3 % event rate in the Bivalirudin group. Aiming for a 0.05 alpha and 0.80 power, a total of 662 patients will be needed. This number will be increased by about 25 % (leading to a total of ≈830 patients) because of uncertainty about expected endpoint rates.
Conclusions
The present trial will give important information on what is the best anticoagulation regimen when performing PCI through the femoral approach in patients at high risk for bleeding.
Similar content being viewed by others
References
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 accf/aha/scai guideline for percutaneous coronary intervention. A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol. 2011;58:e44–e122.
Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008;51:690–7.
Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (grace). Eur Heart J. 2003;24:1815–23.
Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the replace-2 trial. Am J Cardiol. 2007;100:1364–9.
Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92:930–5.
Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–82.
Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the acuity trial. J Am Coll Cardiol. 2007;49:1362–8.
Rao SV, O’Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96:1200–6.
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–76.
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (horizons-ami): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149–59.
Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the acuity trial. JAMA. 2007;298:2497–506.
Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary pci in acute myocardial infarction. N Engl J Med. 2008;358:2218–30.
Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein iib/iiia blockade compared with heparin and planned glycoprotein iib/iiia blockade during percutaneous coronary intervention: Replace-2 randomized trial. JAMA. 2003;289:853–63.
National Kidney Foundation. K/doqi clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266.
World Medical Association Inc. Declaration of helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc. 2009;107:403–5.
Anello C, O’Neill RT, Dubey S. Multicentre trials: a us regulatory perspective. Stat Methods Med Res. 2005;14:303–18.
Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the consort pro extension. JAMA. 2013;309:814–22.
Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, et al. Acute catheterization and urgent intervention triage strategy (acuity) trial: study design and rationale. Am Heart J. 2004;148:764–75.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020–35.
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.
Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007;28:1936–45.
Rao SV, McCoy LA, Spertus JA, Krone RJ, Singh M, Fitzgerald S, et al. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the national cardiovascular data registry cathpci registry. JACC Cardiovasc Interv. 2013;6:897–904.
Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688–96.
Tarantini G, Brener SJ, Barioli A, Gratta A, Parodi G, Rossini R, et al. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials. Am Heart J. 2014;167:401–12. e406.
Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog angioplasty study investigators. N Engl J Med. 1995;333:764–9.
Graham MM, Ghali WA, Faris PD, Galbraith PD, Norris CM, Knudtson ML. Survival after coronary revascularization in the elderly. Circulation. 2002;105:2378–84.
Robertson T, Kennard ED, Mehta S, Popma JJ, Carrozza Jr JP, King 3rd SB, et al. Influence of gender on in-hospital clinical and angiographic outcomes and on one-year follow-up in the new approaches to coronary intervention (naci) registry. Am J Cardiol. 1997;80:26K–39K.
Cox N, Resnic FS, Popma JJ, Simon DI, Eisenhauer AC, Rogers C. Comparison of the risk of vascular complications associated with femoral and radial access coronary catheterization procedures in obese versus nonobese patients. Am J Cardiol. 2004;94:1174–7.
Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein iib/iiia inhibitors: the do tirofiban and reopro give similar efficacy outcome (target) trial. Am Heart J. 2005;149:869–75.
Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the national cardiovascular data registry. Circ Cardiovasc Interv. 2009;2:222–9.
Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31:2501–55.
Sobel M, Fish WR, Toma N, Luo S, Bird K, Mori K, et al. Heparin modulates integrin function in human platelets. J Vasc Surg. 2001;33:587–94.
Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992;67:639–43.
Schulz S, Mehilli J, Ndrepepa G, Neumann FJ, Birkmeier KA, Kufner S, et al. Bivalirudin vs. Unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the isar-react 3 trial. Eur Heart J. 2010;31:582–7.
Rao SV, O’Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:809–16.
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736–47.
Author information
Authors and Affiliations
Corresponding author
Additional information
Article Note
Principal Investigartor: Dr. Carlo Briguori (Laboratory of Interventional Cardiology, Clinica Mediterranea, Naples);
Co-investigators:
– Dr. Amelia Focaccio (Laboratory of Interventional Cardiology, Clinica Mediterranea, Naples);
– Dr. Gabriella Visconti (Laboratory of Interventional Cardiology, Clinica Mediterranea, Naples);
– Dr. Michael Donahue (Laboratory of Interventional Cardiology, Clinica Mediterranea, Naples):
– Dr. Bruno Golia (Department of Cardiology, Clinica Mediterranea, Naples, Italy);
– Dr. Lucio Selvetella (Department of Vascular Surgery, Clinica Mediterranea, Naples, Italy);
– Dr. Bruno Ricciardelli (Department of Cardiology, Clinica Mediterranea, Naples, Italy)
Data Monitoring and Safety Committee
– Dr. Flavio Airoldi (Laboratory of Interventional, Policlinico IRCCS Multimedica, Milan);
– Dr. Davide Tavano, (Laboratory of Interventional, Policlinico IRCCS Multimedica, Milan);
Clinical Events Commitee
– Prof. Gerolama Condorelli, (“Federico II” University of Naples, Italy)
– Cristina Quintavalle, PhD, (“Federico II” University of Naples, Italy)
Clinical Trials and Evaluation Unit Members
Chiara Viviani Anselmi (statistician), Humanitas IRCCS Hospital, Milan, Italy
Rights and permissions
About this article
Cite this article
Briguori, C., Visconti, G., Focaccio, A. et al. Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: Randomised Comparison of Bivalirudin Versus Unfractionated Heparin in Patients at High Risk of Bleeding Undergoing Elective Coronary Stenting Throught The Femoral Approach. Rationale and Design. Cardiovasc Drugs Ther 28, 273–279 (2014). https://doi.org/10.1007/s10557-014-6518-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-014-6518-9